📰 Psychedelics News
Curated updates on microdosing, research, policy, and community.
Filters
What are Penis Envy Mushrooms?
Questions about which strains of Psilocybe cubensis (magic mushrooms) are strongest have been around for as long as underground enthusiasts have been breeding new forms. For many years magic mushroom aficionados use...
EGA Garden States 2022
Entheogenesis Australis (EGA) runs Australia’s premiere psychedelic and plant-medicine conferences. So, when I was offered a ticket in exchange for helping copyedit & proofread the conference journal for EGA Gar...
Gut Feeling: Links Between LSD, Endocannabinoids, and the Microbiome
In the last 10 years, psychiatric interest in the use of psychedelics, such as psilocybin and LSD, has surged. A new study employed mice to examine how LSD could exert changes on the inflammatory response and the gut ...
Abuse Potential: Considerations for Rescheduling MDMA and Psychedelics
Can the meteoric rise of psychedelics and entactogens clear the legal hurdles of abuse potential assessment and rescheduling?
Many Trips, Diminishing Returns: Cross-Tolerance Between LSD and DOI
Psychedelic drugs like LSD powerfully alter consciousness and promote neural plasticity, but drug tolerance occurs rapidly following the first dose. Although the mechanisms that underlie psychedelic tolerance may over...
How To Stop A Psychedelic Trip: The Promise of Ketanserin
Psychedelic trips often unfold without issues, but what if a trip needs to be stopped? Drugs such as benzodiazepines and antipsychotics are recommended as rescue medications and have been around for decades. Can ketan...
Psychedelic Brains In A Dish
Lab grown brains help to shed insight on 5-MeO-DMT mechanisms.
Review of Synthesis Retreats: a Legal Psychedelic Retreat Near Amsterdam
It was a cold spring day in 2019 that I found myself in Zandvoort, a quaint seaside suburb just 30 minutes outside of Amsterdam, to participate in a 3-day Synthesis legal, high-end psilocybin truffle retreat in a 100-...
Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax
The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that it has been granted a Pre-Investigational New Drug (Pre-IND) meeting by the U.S. Food and Drug Administra...
Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment
Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that it has begun a preclinical toxicity study of its novel time-released, dosage-controlled ketamine formulation, ...
Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use
Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus Bioscience, recently announced the development of a tea bag containing psilocybin for use in clinical research. If granted appropriate regu...
atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial
atai has administered the first dosage of their VLS-01 synthetic DMT drug in their Phase 1 single-ascending dose (SAD) trial, with topline results expected to come back sometime during the first half of 2023. VLS-01 i...
Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio
Recently, clinical-stage psychedelic biotechnology company Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) filed for two new provisional patents strengthening the company’s intellectual property portfolio. The compa...
Biomind Labs Complete Phase II Dosing of DMT-Based BMND01 for Treatment-Resistant Depression
Leading psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) has announced the completion of dose administration to 30 healthy subjects with Treatment-Resistant Depression in the Phase II ...